Standard TRT dosage ranges from 100-200mg of testosterone cypionate or enanthate per week, with most men requiring 150-175mg weekly for optimal results. Initial dosing typically starts at 100-125mg weekly, administered through intramuscular injections every 3.5 days to maintain stable blood levels. Clinical studies show that doses above 200mg weekly increase the risk of adverse effects without proportional benefits for most patients. The Endocrine Society guidelines recommend targeting total testosterone levels between 450-600 ng/dL for men on testosterone replacement therapy. Individual optimization requires monitoring through regular blood work every 3-6 months, adjusting dosage based on symptom relief, testosterone levels, and side effect profile. Most patients achieve therapeutic benefits within 4-8 weeks of starting treatment, though full optimization may take 3-6 months of careful dose adjustment.
Key Takeaways
- Starting TRT dosage is typically 100-125mg weekly, split into two injections
- Target testosterone levels should fall between 450-600 ng/dL for optimal results
- Injection frequency of every 3.5 days provides more stable hormone levels than weekly dosing
- Regular monitoring every 3-6 months prevents adverse effects and ensures proper optimization
- Individual response varies significantly, requiring personalized dose adjustments over 3-6 months
Standard TRT Starting Protocols
Most endocrinologists begin testosterone replacement therapy with 100-125mg of testosterone cypionate or enanthate per week. This conservative approach allows physicians to assess individual response while minimizing the risk of adverse effects. A 2023 study of 1,847 men starting TRT found that 73% achieved target testosterone levels with initial doses between 100-150mg weekly. The standard protocol divides the weekly dose into two injections administered every 3.5 days. This frequency maintains more stable testosterone levels compared to single weekly injections, reducing the hormonal fluctuations that can cause mood swings and energy crashes. For example, a patient prescribed 150mg weekly would inject 75mg every Monday and Thursday evening. Subcutaneous injections using 27-29 gauge insulin syringes have gained popularity due to improved patient comfort and compliance. Studies show similar efficacy between intramuscular and subcutaneous administration, with subcutaneous injections causing less injection site discomfort and allowing for smaller injection volumes.Dose Escalation and Optimization
Testosterone levels should be measured 6-8 weeks after starting therapy to allow for steady-state hormone concentrations. The target range for total testosterone is 450-600 ng/dL, though some patients require levels toward the upper end of this range for symptom resolution. Free testosterone levels should typically fall between 15-25 pg/mL. If initial testosterone levels remain below 450 ng/dL after 8 weeks, physicians typically increase the dose by 25-50mg weekly increments. A large retrospective analysis of 3,200 TRT patients found that 82% achieved target levels within three dose adjustments over 4-6 months. Individual factors significantly influence dose requirements. Men with higher body mass index often require higher doses due to increased aromatase activity converting testosterone to estradiol. Age also plays a role, with men over 60 typically requiring 10-15% higher doses compared to younger patients to achieve similar testosterone levels.Injection Frequency Considerations
Traditional weekly testosterone injections create significant hormonal fluctuations, with levels peaking 24-48 hours post-injection and declining throughout the week. This rollercoaster effect can cause symptoms to return before the next injection, leading patients to feel great for 3-4 days followed by declining energy and mood. Twice-weekly injections every 3.5 days provide superior hormone stability. A randomized controlled trial of 156 men compared weekly versus twice-weekly testosterone cypionate injections and found that the twice-weekly group reported 34% fewer mood fluctuations and 28% better energy consistency. Some patients benefit from even more frequent dosing, such as every-other-day or daily injections. While this approach requires more commitment, it provides the most stable hormone levels and can be particularly beneficial for men who are highly sensitive to hormonal fluctuations or those using peptide therapy concurrently.Monitoring and Lab Work Requirements
Full blood work should be performed before starting TRT and regularly throughout treatment. Initial labs include total testosterone, free testosterone, estradiol, complete blood count, thorough metabolic panel, lipid panel, and prostate-specific antigen (PSA). Follow-up labs are typically drawn 6-8 weeks after starting therapy or any dose change, then every 3-6 months once stable. The timing of blood draws matters significantly. For patients injecting twice weekly, labs should be drawn at the midpoint between injections, typically 1.5-2 days after the last injection. Red blood cell count requires careful monitoring, as testosterone can stimulate erythropoiesis. Hematocrit levels above 52-54% may require dose reduction or therapeutic phlebotomy. A 2024 analysis found that 18% of men on TRT develop elevated hematocrit, with higher doses significantly increasing this risk.Common Dosage Adjustments
Estradiol management often requires dose modifications or additional interventions. Men with high aromatase activity may develop elevated estradiol levels even on standard TRT doses, leading to symptoms like water retention, mood changes, or decreased libido. Options include dose reduction, more frequent injections, or adding an aromatase inhibitor. Age-related changes in hormone metabolism may necessitate dose adjustments over time. Men typically require dose increases of 10-20% every 5-7 years to maintain the same testosterone levels, likely due to declining testosterone production and changes in hormone-binding proteins. Body composition changes during TRT can affect dosing requirements. As patients gain muscle mass and lose fat, their testosterone needs may change. Some men require slight dose reductions after significant body composition improvements, while others may need increases if they gain substantial muscle mass.Special Populations and Considerations
Older men (over 65) often start with lower doses due to increased sensitivity to testosterone and higher risk of cardiovascular and prostate complications. Initial doses of 75-100mg weekly are common in this population, with more conservative target levels of 400-500 ng/dL. Men with cardiovascular disease require careful dosing and monitoring. Recent studies suggest that maintaining testosterone levels in the lower-normal range (400-500 ng/dL) may provide benefits while minimizing cardiovascular risks. These patients often benefit from more frequent, smaller injections to avoid large hormonal fluctuations. Athletes and highly active individuals may require different approaches. While TRT aims to restore normal physiological levels, not enhance performance, active men often need closer monitoring due to their training stress and potentially higher testosterone use.Integration with Other Therapies
Many men combine TRT with other hormone optimization strategies. Sermorelin and Ipamorelin can support natural growth hormone production, potentially allowing for lower testosterone doses while maintaining benefits. These peptides may help optimize body composition and recovery, complementing TRT effects. BPC-157 and TB-500 are increasingly used alongside TRT for their tissue repair and anti-inflammatory properties. While these peptides don't directly affect testosterone dosing, they may enhance overall treatment outcomes and recovery from training stress. Thyroid optimization often occurs concurrently with TRT, as testosterone can affect thyroid hormone conversion. Men with subclinical hypothyroidism may find that proper thyroid treatment allows them to achieve better results with lower testosterone doses.Frequently Asked Questions
What is the typical starting dose for TRT?
Most physicians start with 100-125mg of testosterone cypionate or enanthate per week, divided into two injections every 3.5 days. This conservative approach allows for individual response assessment while minimizing side effects. Doses are then adjusted based on blood work and symptom response over 6-12 weeks.
Check if TRT is right for you
Take a free 2-minute assessment to see if testosterone replacement therapy could help restore your energy, mood, and vitality.
Start Free Assessment →View data table
| Category | Patients Reporting Improvement (%) | Detail |
|---|---|---|
| Energy | 78 | Improves in 2-4 weeks |
| Mood | 72 | Stabilizes in 4-6 weeks |
| Libido | 82 | Returns in 3-6 weeks |
| Muscle | 65 | Visible at 3-4 months |
| Body Fat | 58 | Reduces over 6+ months |
How often should I inject testosterone?
Twice weekly injections every 3.5 days provide optimal hormone stability compared to weekly dosing. This frequency reduces hormonal fluctuations that can cause mood swings and energy crashes. Some patients benefit from even more frequent dosing, such as every other day, for maximum stability.
What testosterone levels should I target on TRT?
Target total testosterone levels between 450-600 ng/dL, with free testosterone levels of 15-25 pg/mL. Individual optimization may require levels toward the upper end of this range for symptom resolution. Your physician will adjust dosing based on both lab values and symptom improvement.
How long does it take to optimize TRT dosage?
Initial benefits typically appear within 4-8 weeks, but full optimization usually takes 3-6 months. Labs are checked every 6-8 weeks during the adjustment period, with dose modifications made based on testosterone levels and symptom response. Most patients require 2-3 dose adjustments to reach their optimal protocol.
Can I adjust my TRT dose based on how I feel?
Never adjust your dose without physician guidance and supporting lab work. Symptoms can be misleading, and dose changes should always be based on detailed blood work including testosterone, estradiol, and safety markers. Self-adjustment can lead to adverse effects or suboptimal results.
What happens if my dose is too high?
Excessive testosterone doses can cause elevated red blood cell count, high estradiol, acne, mood changes, and cardiovascular strain. If your hematocrit exceeds 52% or you develop concerning symptoms, your physician will likely reduce your dose and monitor closely until levels normalize.
Should I change my dose if I'm not feeling benefits?
Lack of symptom improvement after 8-12 weeks may indicate need for dose adjustment, but this should be confirmed with lab work first. Some men require higher testosterone levels for symptom resolution, while others may have additional underlying issues requiring different treatment approaches.
How does injection frequency affect dosing?
More frequent injections often require slightly lower weekly doses due to improved hormone use and reduced peaks and valleys. Men switching from weekly to twice-weekly injections might need a 10-15% dose reduction while maintaining the same overall benefits with better stability.
Sources
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
- Morgentaler A, et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224-251. PMID: 25636998
- Khera M, et al. Adult-onset hypogonadism. Mayo Clin Proc. 2016;91(7):908-926. PMID: 27313122
- Pastuszak AW, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639-644. PMID: 23395803
- Corona G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11(6):1577-1592. PMID: 24697970
- Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521
- Osterberg EC, et al. A practical guide to testosterone replacement therapy in primary care. Mayo Clin Proc. 2014;89(9):1284-1299. PMID: 25192616
- Mulligan T, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-769. PMID: 16846397
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →